Jamshedpur Reporter

FAK Inhibitors Competitive Landscape 2032 by DelveInsight | Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutica

 Breaking News
  • No posts were found

FAK Inhibitors Competitive Landscape 2032 by DelveInsight | Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutica

May 08
20:55 2023
FAK Inhibitors Competitive Landscape 2032 by DelveInsight | Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutica
FAK Inhibitors Market

(New York, USA) DelveInsight’s FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

 

Key Takeaways from the FAK Inhibitors Market Report

  • DelveInsight analysis shows that the FAK inhibitors market is expected to grow positively due to several underline factors during the study period (2019–2032).
  • Globally, leading FAK inhibitors companies such as Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries, Immunocore, AstraZeneca, Genentech, and others are developing novel FAK inhibitors that can be available in the FAK inhibitors market in the coming years.
  • Some key FAK inhibitors include VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others.
  • Several FAK inhibitors are awaiting approval, while some FAK inhibitors are in the advanced stages of development. 

 

Discover which FAK inhibitors are expected to grab the major FAK inhibitors market share @ FAK Inhibitors Market Forecast

 

FAK Inhibitors Overview

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is overexpressed and activated in both adult and pediatric malignancies, where it plays critical roles in the regulation of pathogenesis and progression of the malignant phenotype. FAK operates in cancer in two ways: as a kinase activity in the cytoplasm, which is primarily dependent on integrin signaling, and as a scaffolding activity in the nucleus, which is accomplished through networking with various gene expressions. The FAK gene, also known as protein tyrosine kinase 2 (PTK2), is located on human chromosome 8q24.3 and encodes the FAK protein, which is found in many different types of cells and is mostly found in the plasma membrane and cytoplasm. FAK is classified into three domains: N-terminal FERM, core kinase, and C-terminal domains. The FAK FERM region is non-catalytic, and a similar FERM motif may be found in Janus kinase (JAK), another tyrosine kinase.

 

To know more about FAK inhibitors, visit @ https://www.delveinsight.com/sample-request/fak-inhibitors-market

 

Key FAK Inhibitors Drugs and Companies

  • VS-6766 + defactinib: Verastem, Inc.
  • Defactinib: Verastem, Inc.
  • FAK Inhibitor GSK2256098: GlaxoSmithKline
  • VS-6063: Verastem, Inc.
  • Pembrolizumab: Merck Sharp & Dohme LLC
  • PF-04554878: Pfizer
  • IN10018: InxMed
  • KIMMTRAK (tebentafusp): Immunocore
  • ZEJULA (niraparib): GlaxoSmithKline
  • LYNPARZA (olaparib): AstraZeneca
  • AVASTIN (bevacizumab): Genentech

 

Learn more about the FDA-approved FAK inhibitors @ https://www.delveinsight.com/sample-request/fak-inhibitors-market

 

FAK Inhibitors Market Dynamics

The dynamics of the FAK inhibitors market are expected to evolve as leading pharma and biotech companies around the world work hard to develop novel FAK choices with convenient RoA and a better safety profile to treat a wide range of malignancies. Furthermore, the FAK inhibitors pipeline is very robust; many potential therapies are being investigated for the treatment of various cancer, and it is safe to predict that the treatment space will significantly impact the oncology market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the FAK inhibitors market in the 7MM.

 

FAK Inhibitors Market Report Metrics

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
  • Base Year: 2019
  • Key FAK Inhibitors Companies: Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries, Immunocore, AstraZeneca, Genentech, and others
  • Key FAK Inhibitors Therapies: VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others

 

Request for sample page@ https://www.delveinsight.com/sample-request/fak-inhibitors-market

 

 

Scope of the FAK Inhibitors Market Report

  • Therapeutic Assessment: Current Marketed and Emerging FAK Inhibitors 
  • FAK Inhibitors Market Dynamics: Attribute Analysis of Emerging FAK Inhibitors 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, FAK Inhibitors Market Access and Reimbursement

 

Discover more about FAK inhibitors in clinical trials @ https://www.delveinsight.com/sample-request/fak-inhibitors-market

 

Table of Contents

1. FAK Inhibitors Market Key Insights

2. FAK Inhibitors Market Report Introduction

3. FAK Inhibitors Market Overview at a Glance

4. FAK Inhibitors Market Executive Summary

5. Disease Background and Overview

6. FAK Inhibitors Marketed Drugs

7. FAK Inhibitors Emerging Drugs

8. Seven Major FAK Inhibitors Market Analysis

9. FAK Inhibitors Market Outlook

10. Potential of Current and Emerging Therapies

11. KOL Views

12. FAK Inhibitors Market Drivers

13. FAK Inhibitors Market Barriers

14. Unmet Needs

15. SWOT Analysis

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Recent Posts

Guillain-Barré Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon

Read Full Article

Categories